OBR Daily Commentary

forumImage

Oncologists Disagree On Use Of Value To Guide Cancer Treatments

(Stanford Medicine/Scope blog) Apr 4, 2018 - A new study found that oncologists have divergent views on how to use “value” to guide cancer treatment recommendations.

Read Article arrow

Thomas Marsland, MD (Posted: April 06, 2018)

quotes

So again the "value" question....I share my dear friend Ted Okon's comments about sample size of this study. 31 oncologists in a nation of over 5000 medical oncologist is hardly representative. With that said, value is always problematic. Value to whom?? The patient, the payer, the employer, the provider??? Plus the cost is a constantly changing target. Drugs that were considered horribly expensive may be considered a deal when viewed in light of $500,000 Car-T cell therapy. Organized medicine such as NCCN, ASCO and COA have all weighed in with some suggestions on value. Clearly clinical outcomes, quality of life, and cost are all important in the decision process. I always at least briefly discuss cost with the patient and I suspect most oncologist do. Anyway I suspect this issue will be with us for a long time as I don't see pricing coming down soon.

quotes

Reply

Ted Okon (Posted: April 05, 2018)

quotes

A total of 31 oncologists and only from academic centers, medical centers, and the VA. No community oncologists. Not representative of anything but 31 random oncologists. Not really research.

quotes

Reply

Ted Okon (Posted: April 05, 2018)

quotes

Terrible research. Biased sample (not one community oncologist) and making judgements about where oncologists stand on "value" is completely meaningless. Surprised it was published anywhere.

quotes

Reply

Add Comment 3 Comment(s)

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...